Management of post-transplant lymphoproliferative disorders

Take home messages Reduction of immune suppression followed by rituximab has become the standard of care in the majority of post-transplant lymphoproliferative disorders. Currently pre-emptive therapy is only justified in allogeneic hematopoietic stem cell recipients. Adoptive immunotherapy is a very promising therapeutic modality, both in pre-emptive setting and as treatment of established Epstein-Barr virus-positive post-transplant lymphoproliferative disorder. However, use is still restricted because of labor-intensive procedure, reimbursement issues, and availability problems.